Assessing The Healthcare Selloff

May 04, 2019 5:47 AM ETUNH, IBB, XLV, XBI, VHT, IYH, HQH, LABU, HQL, FBT, BBH, CURE, THQ, FHLC, LABD, PBE, CNCR, BBC, FXH, RXL, BBP, RYH, UBIO, ZBIO, LNGR, RXD, BTEC, JHMH, GNOM

Summary

  • Recent political rhetoric over potentially sweeping changes to Medicare and ongoing scrutiny of prescription drug prices have led to a correction in the healthcare sector.
  • We believe the selling pressure has been sentiment driven and that strong fundamentals remain intact across most subsectors.
  • We see the best opportunities in biotechnology and pharmaceuticals. We are more cautious to add to positions in managed care, although we believe it will outperform over the longer term.

By Marshall Gordon and Nicholas Wu, PhD

Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration's push to lower prescription drug prices, we have not seen a material change in near-term fundamentals. The whole move has been sentiment driven, resulting in changes in the long-term or terminal value of companies across healthcare that could present selective opportunities.

The broad healthcare sector has underperformed the S&P 500 by about 700 basis points over the last month, but we are probably not at a bottom for most subsectors. Concerns will likely remain elevated through the 2020 election cycle, and possibly longer (if Democrats sweep with a more extreme candidate). At this point, most subsectors are still 30% to 40% from trough valuations reached in the 2008-2010 downturn (Exhibit 1). Relative to that period, industry fundamentals and growth are healthier, so valuations may not bottom as low as in the past.

Medicare for All Pressures Managed Care Stocks

Managed care stocks have seen the largest correction thus far, impacted by the growing "Medicare for All" clamor from progressive Democrats on Capitol Hill. True "Medicare for All," i.e. single payor, is an existential risk, but one we think is improbable. Federal and state governments likely need managed care to bend the cost curve of expensive Medicaid and Medicare Advantage programs. Managed care suffered through a similar dynamic from 2008 to 2010 but persevered, with companies like UnitedHealth Group (UNH) rebounding to all-time highs over time. The prescription drug value chain, which includes pharmacy benefit managers and other distributors, meanwhile faces real near-term business challenges and regulatory risks. These include recently announced government plans to reform rebates in Medicare Part D

This article was written by

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We convey these ideas to investors on a frequent basis through investment commentaries and thought leadership and look forward to sharing the latest insights from our white papers, blog posts as well as videos and podcasts.

Disclosure: I am/we are long UNH. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Past performance is no guarantee of future results. The opinions and views expressed herein are of the Portfolio Managers listed as of the date shown, and may differ from other managers, or the firm as a whole, and are not intended to be a forecast of future events, a guarantee of future results, or investment advice. The statistics have been obtained from sources believed to be reliable, but the accuracy and completeness of this information cannot be guaranteed. Neither ClearBridge Investments nor its information providers are responsible for any damages or losses arising from any use of this information.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.